Open an account

Pharming Group NV

PHAR · NYSE

$11.20+$0.53 (+4.97%)TodayMarket closed ·
Prev close $10.67

About PHAR

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company employs 407 full-time employees The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Employees
407
Headquarters
Leiden, Zuid-Holland
Listed
Jul 2, 1998
Sector
Health Care
Industry
Biotechnology
Website
pharming.com

PHAR key statistics

Market cap
667.72M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
18.10K
Volume
25.79K
Open price
$11.32
High today
$11.45
Low today
$10.76
52 Week high
$21.34
52 Week low
$9.11

Pharming Group NV (PHAR) at a glance

Pharming Group NV (PHAR) last traded at $11.20, with a market cap of 667.72M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $10.76 and $11.45. The current price is 4.1% above the day's low and 2.2% below its high.

Volume so far is 25.79K shares, above the average of 18.10K shares a day.

Over the past year Pharming Group NV has ranged from $9.11 to $21.34, and now sits 17% of the way up that range.

Pharming Group NV met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.002 per share against an estimate of $0.0201.

The average analyst price target is $23.95, 113.9% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $23.95
Low
$20.63
Now
$11.20
High
$29.18

PHAR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 415.4% on average.

  1. Q3 FY24: reported -$0.002 per share against an estimate of -$0.0026
  2. Q4 FY24: reported $0.005 per share against an estimate of $0.0069
  3. Q1 FY25: reported -$0.022 per share against an estimate of -$0.0155
  4. Q2 FY25: reported $0.006 per share against an estimate of -$0.0258
  5. Q3 FY25: reported $0.01 per share against an estimate of -$0.001
  6. Q4 FY25: reported $0.008 per share against an estimate of $0.0086
  7. Q1 FY26: reported -$0.007 per share against an estimate of $0.0067
  8. Q2 FY26: reported $0.002 per share against an estimate of $0.0201

PHAR news

  • Avi Kapoor

    Crude Oil Moves Higher; Lockheed Martin Posts Upbeat Earnings

  • Press releaseGlobe Newswire

    Pharming Group to participate in September investor conferences

  • Press releasePRNewswire

    Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky

  • Press releaseBusiness Wire

    Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • Press releaseBusiness Wire

    Pharming Group N.V. (PHAR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • Press releaseBusiness Wire

    Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  • Press releaseBusiness Wire

    PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)

  • Press releasePRNewswire

    PHAR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Pharming Group

Similar companies

Companies in the same industry as Pharming Group NV

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.